摘要
目的 探讨非小细胞肺癌(non-small cell lung cancer, NSCLC)患者化疗后血清p38水平与骨髓抑制程度的相关性。方法 选取130例初诊为NSCLC术后的患者,采用酶联免疫法检测患者化疗前后血清中p38的表达水平,统计骨髓抑制发生率及分析化疗后血清中p38水平与骨髓抑制程度的相关性。结果 根据骨髓抑制分度标准分为重度组(n=27)、轻度组(n=83)、正常组(n=20),化疗后骨髓抑制发生率为84.6%,化疗后血清p38变化水平较化疗前升高,差异具有统计学意义(P<0.05);化疗后血清p38水平与化疗后骨髓抑制分级呈正相关,差异具有统计学意义(R=0.517,P<0.05)。结论 血清p38水平与非小细胞肺癌化疗后骨髓抑制存在相关性,p38可能参与了化疗后骨髓抑制的发生。
Objective To investigate the correlation between serum P38 level and myelosuppression in patients with non-small cell lung cancer after chemotherapy.Methods A total of 130 patients diagnosed as NSCLC were selected.Enzyme-linked immunosorbent assay(ELISA)was used to detect the expression levels of p38 in serum before and after chemotherapy.The incidence of myelosuppression was recorded,and the correlation between serum p38 levels after chemotherapy and the degree of bone marrow suppression was analyzed.Results The patients were divided into a severe group(n=27),a mild group(n=83),and a normal group(n=20)based on graduation standard for myelosuppression.The incidence of chemotherapy-induced myelosuppression after chemotherapy was 84.6%.The serum p38 levels increased significantly after chemotherapy(P<0.05).There was a positive correlation between serum p38 levels after chemotherapy and the grading of bone marrow suppression,which was statistically significant(r=0.517,P<0.05).Conclusion The level of Serum p38 is correlated with myelosuppression after chemotherapy in non-small cell lung cancer,and p38 may be involved in the occurrence of myelosuppression after chemotherapy.
作者
罗莲
陈梓林
周娜
颜磊
黄嘉琪
黄多美
陈勇
LUO Lian;CHEN Zilin;ZHOU Na;YAN Lei;HUANG Jiaqi;HUANG Duomei;CHEN Yong(Department of Hematology and Oncology,Shaoyang Hospital Affiliated to Nanhua University,Shaoyang 422000,China;Department of Obstetrics,Shaoyang Central Hospital,Shaoyang 422000,China)
出处
《邵阳学院学报（自然科学版）》
2024年第2期110-116,共7页
Journal of Shaoyang University：Natural Science Edition
基金
邵阳市科学技术局重大专项和重点项目(2020NS36)
邵阳市科学技术局一般项目(2021GZ037)。
关键词
血清p38水平
非小细胞肺癌
化疗
骨髓抑制
serum P38 level
non-small cell lung cancer
chemotherapy
myelosuppression
